EMA Authorised: Fintepla (fenfluramine hydrochloride) — UCB Pharma S.A.

View source ↗

Summary

The EMA authorised Fintepla (fenfluramine hydrochloride) from UCB Pharma S.A. for epilepsies with myoclonic seizures, an orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsies
• Myoclonic Epilepsy

Drugs mentioned

• Fintepla (Fenfluramine)

Snippet

Status: Authorised. Therapeutic area: Epilepsies, Myoclonic. MAH: UCB Pharma S.A.. Decision date: 26/03/2026. Orphan medicine